Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) CFO Sally Bridget Lawlor purchased 10,244 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were acquired at an average price of $4.88 per share, for a total transaction of $49,990.72. Following the purchase, the chief financial officer directly owned 10,684 shares of the company’s stock, valued at approximately $52,137.92. This represents a 2,328.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Quoin Pharmaceuticals Stock Up 4.7%
Quoin Pharmaceuticals stock traded up $0.29 on Tuesday, hitting $6.51. The company’s stock had a trading volume of 274,471 shares, compared to its average volume of 1,602,162. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a one year low of $3.25 and a one year high of $41.80. The firm has a market cap of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50. The company has a fifty day moving average price of $4.77 and a 200-day moving average price of $5.89.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). Analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 EPS for the current year.
Institutional Trading of Quoin Pharmaceuticals
Wall Street Analyst Weigh In
QNRX has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. ThinkEquity initiated coverage on Quoin Pharmaceuticals in a research note on Monday, June 15th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Quoin Pharmaceuticals currently has an average rating of “Hold”.
Read Our Latest Analysis on Quoin Pharmaceuticals
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.
See Also
- Five stocks we like better than Quoin Pharmaceuticals
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
